MedTrace Logo

Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*

NCT02212964 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2016-03-31

No results posted yet for this study

Summary

Using a multi-echo gradient echo sequence to calculate R2\* and quantitative susceptibility maps and well as susceptibility-weighted imaging post processing the investigators hypothesize that the investigators would be able to distinguish between pseudoprogression and true progression with the use of an easily implementable sequence on clinical MRI scanners.

Conditions

Sponsors & Collaborators

  • London Regional Cancer Program, Canada

    collaborator OTHER

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    collaborator OTHER

  • Centre for Functional and Metabolic Mapping

    lead OTHER

Principal Investigators

  • Ravi S Menon, PhD · Western University, Canada

  • Glenn Bauman, MD · Western University, Canada

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02212964 on ClinicalTrials.gov